Investigational combination products
cancer
CANCER
Atezolizumab is a humanized IgG1 Mab that targets PD-L1 and inhibits the interaction between PD-L1 and its receptors, PD-1 and B7-1 (also known as CD80), both of which function as inhibitory receptors expressed on T cells. Therapeutic blockade of PD-L1 binding by atezolizumab has been shown to enhance the magnitude and quality of tumor-specific T-cell responses. Atezolizumab has minimal binding to Fc receptors, thus eliminating detectable Fc-effector function and the associated antibody-mediated clearance of activated effector T cells.Tiragolumab (formerly MTIG7192A) is a fully human IgG1/κ Mab derived in open monoclonal technology rats that binds to TIGIT and prevents its interaction with the poliovirus receptor. The recombinant antibody is produced in Chinese hamster ovary (CHO) cells and consists of two heavy chains (456 amino acid residues each) and two light chains (220 amino acid residues each). There are two N-linked glycosylation sites (Asn306) in the Fc domain. The predicted molecular weight of tiragolumab is 148,409 Da (peptide chains only, without heavy chain C-terminal lysine residue). By binding to TIGIT, tiragolumab blocks its interaction with a protein called CD155 (poliovirus receptor) that can suppress the body’s immune response. Therapeutic blockade of TIGIT by means of tiragolumab represents an attractive strategy for cancer therapy and is expected to enhance the magnitude and quality of the tumor-specific T-cell responses, which may result in improved meaningful anti-tumor activity when tiragolumab is used as a single agent or in combination with other ICIs.